Aeterna Zentaris Inc. (AEZS) On December 28th Aeterna Zentaris announced that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) on a Special Protocol Assessment (“SPA”) for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. Optimistic market reaction on this announcement boosted AEZS shares […]
We profiled Æterna Zentaris (AEZS) stock as a highly speculative investment opportunity at around $.44. AEZS shares almost doubled in value for the last six weeks and still on their way to over a dollar. Market favored Æterna’s stock with Roth Capital initiation a “Buy” share/price target of $1.75 and even more price goal expectations from the […]
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced on June 28th that its Japanese partner Yakult Honsha (“Yakult”) (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company’s oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient […]
Shares of Keryx Biopharmaceuticals (Nasdaq:KERX) got slammed today after the company announced that their cancer drug trial, KRX-0401 (in-licensed by Keryx from AeternaZentaris Inc. (AEZS) in the United States, Canada and Mexico), failed. Ron Bentsur, Chief Executive Officer of Keryx, stated: We are all extremely disappointed with the results of the study. We thank the […]
